Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov-Dec;1(6):531-8.
doi: 10.4161/mabs.1.6.10195. Epub 2009 Nov 29.

Raxibacumab

Sohini Mazumdar  1
Affiliations
Review

Raxibacumab

Sohini Mazumdar. MAbs. 2009 Nov-Dec.

Abstract

Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen. HGS is currently providing stockpiles of the agent to the US government for use in the prevention and treatment of inhalation anthrax. As of May 2009, the candidate was undergoing review by the US Food and Drug Administration. The availability of bioterrorism countermeasures has become more important since the September 2001 anthrax attacks, and development of raxibacumab is a significant advance in this area.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov. 2006;5:191–195. - PMC - PubMed
    1. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287:2236–2252. - PubMed
    1. Schneemann A, Manchester M. Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol. 2009;4:35–43. - PMC - PubMed
    1. Zmuda JF, Zhang L, Sosnovtseva S, Bukreyeva N, Beebe L, Hunt R, et al. Detection of host-derived neutralizing antibodies against anthrax protective antigen (PA) in PAmAb-treated monkeys surviving lethal spore challenge: relationship to secondary exposure immunity; American Society of Microbiology Biodefense Meeting; 2004. Abstract 65H. http://www.hgsi.com/images/pdf/asm_monkey_rechallenge.pdf.
    1. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361:135–144. - PubMed